Tag Archives: HFAC

SpaceX gets ready to launch first all-civilian crew to orbit

With a view of the iconic Vehicle Assembly Building at left, a SpaceX Falcon 9 rocket soars upward from Launch Complex 39A carrying the company’s Crew Dragon Endeavour capsule and four Crew-2 astronauts towards the International Space Station at NASA’s Kennedy Space Center in Cape Canaveral, Florida, U.S. April 23, 2021. NASA/Ben Smegelsky/Handout via REUTERS

Sept 12 (Reuters) – Yet another billionaire entrepreneur is set to ride into space this week, strapped inside the capsule of a SpaceX rocketship, as part of an astro-tourist team poised to make history as the first all-civilian crew launched into Earth orbit.

Jared Isaacman, the American founder and chief executive of e-commerce firm Shift4 Payments (FOUR.N), will lead three fellow spaceflight novices on a trip expected to last three days from blastoff at Cape Canaveral, Florida, to splashdown in the Atlantic.

The 38-year-old tech mogul has plunked down an unspecified but presumably exorbitant sum to fellow billionaire and SpaceX owner Elon Musk to fly Isaacman and three specially selected travel mates into orbit aboard a SpaceX Crew Dragon capsule.

The crew vehicle is set for blastoff from NASA’s Kennedy Space Center atop one of Musk’s reusable Falcon 9 rockets, with a 24-hour targeted launch window that opens at 8 p.m. EDT (0000 GMT) on Wednesday. That window will be narrowed, or possibly altered, a few days before, depending on weather.

Dubbed Inspiration4, the orbital outing was conceived by Isaacman primarily to raise awareness and support for one of his favorite causes, St. Jude Children’s Research Hospital, a leading pediatric cancer center. He has pledged $100 million personally to the institute.

But a successful mission would also help usher in a new era of commercial space tourism, with several companies vying for wealthy customers willing to pay a small fortune to experience the exhilaration of supersonic flight, weightlessness and the visual spectacle of space.

Setting acceptable levels of consumer risk in the inherently dangerous endeavor of rocket travel is also key, and raises a pointed question.

“Do you have to be both rich and brave to get on these flights right now?” said Sridhar Tayur, a professor of operations management and new business models at Carnegie Mellon University in Pittsburgh, in an interview with Reuters on Friday.

BEYOND THE BILLIONAIRE SPACE RACE

SpaceX is easily the most well-established player in the burgeoning constellation of commercial rocket ventures, having already launched numerous cargo payloads and astronauts to the International Space Station for NASA.

Rival companies Virgin Galactic (SPCE.N) and Blue Origin both recently celebrated their debut astro-tourism missions with their respective founding executives – billionaires Richard Branson and Jeff Bezos – each going along for the ride.

But those two high-profile flights were suborbital in scale, sending their crews of citizen astronauts to space and back in a matter of minutes.

The SpaceX flight is designed to carry its four passengers where no all-civilian crew has gone before – into Earth orbit.

There, they will circle the globe once every 90 minutes at more than 17,000 miles per hour, or roughly 22 times the speed of sound. The target altitude is 575 kilometers, or nearly 360 miles high, beyond the orbits of the International Space Station or even the Hubble Space Telescope.

Like Blue Origin, the 20-story-tall SpaceX launch vehicle and crew capsule will take off vertically from a launch pad on a flight directed entirely from the ground.

Branson’s suborbital rocket plane, by contrast, had two highly trained pilots at the controls as it carried its four rear-seat passengers 50 miles high.

The Inspiration4 crew will have no part to play in operating their spacecraft, despite some largely honorary titles, though two members – Isaacman and geoscientist Sian Proctor – are licensed pilots.

Isaacman, who is rated to fly commercial and military jets, has assumed the role of mission “commander,” while Proctor, 51, once a NASA astronaut candidate herself, has been designated as the mission “pilot.” She was selected to join the team through an online contest run by Shift4 Payments.

Rounding out the crew are “chief medical officer” Hayley Arceneaux, 29, a bone cancer survivor turned St. Jude physicians’ assistant, and mission “specialist” Chris Sembroski, 42, a U.S. Air Force veteran and aerospace data engineer. He won a seat in a sweepstake that drew 72,000 applicants and has raised over $100 million in St. Jude donations.

The four crewmates have spent the past five months undergoing rigorous preparations, including altitude fitness, centrifuge (G-force), microgravity and simulator training, emergency drills, classroom work and medical exams.

Inspiration4 officials stress that the mission is more than a joyride. Once in orbit, the crew will perform medical experiments with “potential applications for human health on Earth and during future spaceflights,” the group said in its press materials.

Appearing in a promotional clip for a Netflix (NFLX.O) documentary series on the mission, Arceneaux said a big part of her motivation was to kindle hope in her cancer patients.

“I’m getting to show them what life can look like after cancer,” she said.

Reporting by Steve Gorman in Los Angeles, Editing by Rosalba O’Brien

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Each COVID-19 surge poses a risk for healthcare workers: PTSD

Sept 5 (Reuters) – Nurse Chris Prott’s knees jump, his heart races, his mouth goes dry and his mind floods with dark memories when he talks about working in the Milwaukee VA Medical Center’s intensive care unit (ICU) during pandemic surges.

Prott shares a struggle common to many of the military veterans for whom he has cared for years: symptoms of post-traumatic stress disorder (PTSD).

Prott was among a half dozen ICU staffers who told Reuters of symptoms such as waking from nightmares bathed in sweat; flashbacks to dying patients during the pandemic’s fear-filled early days; flaring anger; and panic at the sound of medical alarms. Those whose symptoms last longer than one month and are severe enough to interfere with daily life can be diagnosed with PTSD.

The surging Delta variant is heaping on fresh trauma as the United States and other nations begin to study PTSD in health workers. Data already showed that U.S. health workers were in crisis before COVID-19.

While PTSD is associated with combat, it can arise among civilians after natural disasters, abuse or other trauma. Health workers can be reluctant to equate their experience with that of returning soldiers.

“I feel like a schmuck calling it PTSD,” Prott said. “It took me a long time to be able to talk to somebody because I see guys with real PTSD. What I’ve got going on, it’s nothing in comparison, so you feel guilty for thinking that.”

Psychiatrist Dr. Bessel van der Kolk knows better.

“On the surface, a nurse at your local hospital will not look like a guy coming back from Afghanistan,” said the author of “The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma.” “But underneath it all, we have these core neurobiology-determined functions that are the same.”

Pre-pandemic studies showed that rates of PTSD in front-line health workers varied from 10% to 50%. The suicide rate among doctors was more than twice that of the general public.

The American Medical Association (AMA) has tapped a military psychologist and the Department of Veterans Affairs’ (VA) National Center for PTSD to help it measure the pandemic’s impact.

Texas Tech University Health Science Center psychiatry resident Dr. Huseyin Bayazit and researchers in his native Turkey surveyed 1,833 Turkish health workers last autumn. The results, presented in May at an American Psychiatric Association meeting, showed a PTSD rate of 49.5% among nonphysicians and 36% for doctors. Rates of suicidal thoughts increased as workers spent more time on COVID-19 units.

Unions want to mitigate trauma by setting national rules for the number of patients under each nurse’s care. Workers say they should not have to pay for therapy, medication, and other interventions.

The AMA and other groups want more confidentiality for doctors who seek mental health services. Most ICU staff who discussed PTSD with Reuters requested anonymity for fear of repercussions at work.

New York’s Mount Sinai Health System and Chicago’s Rush University System for Health provide free, confidential mental health services.

Mount Sinai’s new Center for Stress, Resilience, and Personal Growth offers a military-inspired “Battle Buddies” peer-support program for nurses. A  chaplain  from Rush’s “Road Home” program for veterans runs a “post-traumatic growth” bereavement support group for ICU nurses.

The VA system provides no-cost, short-term mental health counseling through its employee assistance program. Many local VA facilities supplement those with spiritual counseling and crisis incident response teams, a spokesperson said.

‘YOU HAVE TO DEAL WITH IT’

About 5,000 U.S. physicians quit every two years due to burnout, said Dr. Christine Sinsky, an AMA vice president. The annual cost is about $4.6 billion – including lost revenue from vacancies and recruitment expenses, she said.

Hospital survey results in March led the Department of Health and Human Services to warn “staffing shortages have affected patient care, and that exhaustion and trauma have taken a toll on staff’s mental health.”

Trauma surgeon Dr. Kari Jerge volunteered to work in a Phoenix COVID-19 ward during last winter’s surge. She turned down substantially more pay to return to the ICU after the Delta variant surge.

Jerge encourages others to prioritize “self-preservation,” but worries about the loss of expertise. “There is infinite value in a nurse who’s been working in the ICU for 20 years and just has a gut feeling when something’s going wrong with a patient,” she said.

Nurse Pascaline Muhindura, 40, who cares for COVID-19 patients in Kansas City, Missouri, has advocated for health worker safety since losing a co-worker to the disease early in the pandemic.

“It keeps getting worse and worse. We are heading back to that place – that woke up those emotions again,” said Muhindura, who added that many employers do not offer adequate insurance coverage for therapy.

An ICU fosters the kind of camaraderie forged in battle. A group of Southern California COVID-19 nurses got matching tattoos. Health workers commiserate over crying their way home after tough shifts, support each other on social media, and push colleagues to seek help.

“There is nothing wrong with feeling this way,” said VA nurse Prott. “You have to deal with it though.”

Reporting by Lisa Baertlein in Los Angeles Editing by Donna Bryson and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Six U.S. states do not join $26 bln opioid settlements with distributors, J&J

Aug 23 (Reuters) – At least six U.S. states, including Georgia, did not fully sign on to a proposed $26 billion settlement with three drug distributors and Johnson & Johnson (JNJ.N), which have been accused of fueling the nation’s opioid epidemic, according to the states’ attorneys general.

States had until Saturday to decide whether to support the $21 billion proposed settlement with McKesson Corp (MCK.N), AmerisourceBergen Corp (ABC.N) and Cardinal Health Inc (CAH.N) and a separate $5 billion agreement with J&J.

But in a sign that talks were continuing despite the passing of the deadline, Georgia – the most populous hold-out state – on Monday indicated it could wind up backing the agreement.

“We have not rejected the deal, but we have not joined because at the present time joining the national settlements does not guarantee the best outcome for Georgia and its counties, cities and citizens,” said an emailed statement from the office of the attorney general, Christopher Carr. “We remain active in representing Georgia throughout negotiations, and we’re going to continue to get input from Georgia stakeholders.”

The state will litigate its claims if needed, the statement said.

New Mexico, Oklahoma, Washington and West Virginia also declined to join the deals, their state attorneys general said. New Hampshire agreed to the settlement with distributors but not the J&J agreement.

The complex settlement formula envisions at least 44 states participating, but ultimately the companies get to decide whether a “critical mass” has joined and whether to finalize the deal.

The size of the settlement is based on the number of participating states. Those that decline to join will instead seek a larger recovery by continuing to fight the defendants in the courts. The companies have already paid hundreds of millions in verdicts and other settlements.

The deal, which was unveiled by 14 state attorneys general on July 21, aims to resolve more than 3,000 lawsuits accusing the distributors of ignoring red flags that pain pills were being diverted into communities for illicit uses and that J&J played down the risks of opioid addiction.

The money would go toward funding treatment and other services.

The companies deny wrongdoing, saying the drugs were approved by the U.S. Food and Drug Administration and that responsibility for ballooning painkiller sales lies with others, including doctors and regulators.

McKesson said the companies have until Sept. 4 to determine if there is sufficient support for the agreements and said that process is ongoing. Cardinal Health and AmerisourceBergen declined to comment and J&J did not immediately respond to a request for comment.

The support of two other states, Nevada and Alabama, also appeared to be in doubt, according to sources familiar with the situation.

Nevada’s attorney general declined to comment and the Alabama attorney general did not respond to a request for comment.

The participation of states is tied closely to that of their local governments, which brought the majority of the lawsuits. Cities and counties within participating states would have through Jan. 2 to sign on. Ultimately, $10.7 billion of the settlement money is tied to the extent to which localities participate.

North Carolina Attorney General Josh Stein, a lead negotiator, last month said he expected “well north” of 40 states to join.

Reporting by Nate Raymond in Boston and Tom Hals in Wilmington, Delaware;
Editing by Noeleen Walder and Karishma Singh

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

As Delta spreads, some travelers double up on COVID-19 vaccine in U.S.

WASHINGTON, Aug 16 (Reuters) – Alison Toni felt lucky to get Sinovac’s COVID-19 vaccine in Chile earlier this year. A month later, she was in Minnesota getting vaccinated again.

Toni, an American living in Chile, was visiting her parents in Minneapolis in April when she got her first Pfizer shot at a CVS pharmacy. She traveled back for the second dose in June. She did not disclose being previously vaccinated.

“They didn’t ask, and I didn’t tell,” said Toni, 55. She took that step after reading that China’s Sinovac vaccine had a lower efficacy than the Pfizer Inc shot, developed with German partner BioNTech, and the Moderna Inc shot, both widely available in the United States. She also consulted with her doctor beforehand.

Toni is among the group of people coming from abroad who have been vaccinated a second time, or plan to do so, in the United States.

Their reasons range from concerns that the vaccines immediately available to them were not effective enough, fears that they require extra protection against the fast-spreading Delta variant, or a need to meet specific requirements for work or travel. Some are seeking medical advice, others are relying on their own research.

A few countries are also beginning to offer a third booster dose to their citizens based on evidence that the initial protection from vaccines wanes over time, or that an extra shot may help prevent infection against Delta, particularly for older people or those with weak immune systems.

Public health officials have not determined if booster doses are needed for the general population, and there is not yet much data on the relative risks and benefits of complete revaccination.

“It is probably more than is needed,” said Jason Gallagher, an infectious diseases expert at Temple University’s School of Pharmacy. “A fourth dose is probably a waste; a third dose is probably unnecessary for a lot of people.”

The World Health Organization (WHO) has urged countries to hold off on boosters while many people worldwide wait to receive their first doses.

Thirty-six-year-old Chilean engineer Ricardo Dayne, who first received Sinovac’s vaccine at home in April got his first Pfizer shot in New York in June.

“Everyone was also talking about the need to have a booster, so I decided to have it.”

‘PROCESS NEEDS TO BE FIXED’

The U.S. Food and Drug Administration (FDA) last week authorized a third vaccine dose for immunocompromised people. Government health officials have estimated that would apply to less than 3% of the adult U.S. population, but have said that eventually, boosters may be required more broadly.

In the meantime, a surplus of vaccines in the United States, along with a decentralized healthcare system, has made it easier for people to show up at pharmacies and vaccination centers for extra doses. The U.S. Centers for Disease Control and Prevention estimates that over 1.2 million Americans have already received at least one extra dose following their initial inoculation.

When asked about travelers doubling up on vaccines, Moderna told Reuters its vaccine is not authorized for this purpose and J&J directed Reuters to the FDA and CDC. Pfizer did not immediately respond to a request for comment.

A CVS Health Corp spokesperson said the company’s policy is to turn away patients who have been fully vaccinated at one of its pharmacies, or who disclose that they have been fully vaccinated elsewhere. A Walgreens spokesperson said its pharmacies ask patients if they have been vaccinated during the appointment process and have alerts in place to check.

Graduate student Jing Wu, 22, said he had no choice. Wu received the Sinovac vaccine in December while in China before moving to the United States to attend Princeton University.

He heard Princeton was planning to require proof of an FDA-approved vaccine. The university’s health service urged him to get vaccinated again and said it would be safe.

He was not reassured.

“I was nervous and stressed about it, but in April I got vaccinated (again),” he said, this time with the Johnson & Johnson shot.

Princeton announced the policy on April 20 but later decided to accept any WHO-approved vaccine, including Sinovac. The university’s health website still states that “there is no known harm from taking additional” vaccines.

The university did not respond to requests for comment.

“If I knew back then the Chinese vaccine would be enough, I wouldn’t have done it,” Wu said.

The United States is developing a plan to require nearly all foreign visitors be fully vaccinated, potentially creating similar issues for many people inoculated with vaccines not approved by the FDA.

Britain and the European Union’s lists of approved vaccines do not include shots made in Russia or China, which have been used in many countries.

Governments should standardize their definition of fully vaccinated to include shots that may not be approved in their countries, but which are still effective, said Dr Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security.

“This whole process needs to be fixed, otherwise, as we get more vaccines and more people traveling, this will only happen more,” Adalja said.

Reporting by Ahmed Aboulenein; Additional reporting by Aislinn Laing in Santiago, Carl O’Donnell and Michael Erman in New York; Editing by Michele Gershberg and Aurora Ellis

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

U.S. states to unveil $26 billion opioid settlement with drug distributors, J&J – sources

A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake

July 19 (Reuters) – U.S. state attorneys general are expected this week to unveil a $26 billion settlement resolving claims that three major drug distributors and drugmaker Johnson & Johnson helped fuel a nationwide opioid epidemic, people familiar with the matter said on Monday.

Distributors McKesson Corp (MCK.N), Cardinal Health Inc (CAH.N) and AmerisourceBergen Corp (ABC.N) would pay a combined $21 billion, while Johnson & Johnson (JNJ.N) would pay $5 billion. New York on Tuesday is expected to announce the distributors have agreed to a $1 billion-plus settlement with the state, a source said.

The ultimate settlement pricetag could fluctuate depending on the number of states and political subdivisions that agree to the deal or reject it and pursue litigation on their own in hopes of a bigger payout down the line.

More than 40 states are expected to support the nationwide settlement, two sources said. States will have 30 days to decide whether to join the global accord then more time to try to convince their cities and counties to participate in the deal, the sources said.

McKesson has previously said that of the $21 billion the three distributors would pay over 18 years, more than 90% would be used to remediate the opioid crisis while the rest, about $2 billion, would be used to pay plaintiffs’ attorney fees and costs.

Several states have passed laws or reached agreements with their political subdivisions to govern how settlement proceeds would be allocated in the event of a nationwide settlement.

The financial terms are in line with prior disclosures by the three distributors and J&J about what they expected to have to pay following long-running settlement talks.

“There continues to be progress toward finalizing this agreement and we remain committed to providing certainty for involved parties and critical assistance for families and communities in need,” J&J said in a statement.

McKesson and Cardinal Health had no comment while AmerisourceBergen said it does not comment on “rumor and speculation.” They have all previously denied wrongdoing.

Nearly 500,000 people died from opioid overdoses in the United States from 1999 to 2019, according to the U.S. Centers for Disease Control and Prevention (CDC). The opioid crisis appeared to worsen during the COVID-19 pandemic.

The CDC last week said provisional data showed that 2020 was a record year for drug overdose deaths with 93,331, up 29% from a year earlier. Opioids were involved in 74.7%, or 69,710, of those overdose deaths. read more

The distributors were accused of lax controls that allowed massive amounts of addictive painkillers to be diverted into illegal channels, devastating communities, while J&J was accused of downplaying the addiction risk.

Governments have said the money will be used to fund addiction treatment, family support programs, education and other health initiatives to address the crisis.

Other settlements are also being negotiated, with the opioid makers Purdue Pharma and Mallinckrodt Plc (MCDG.MU) now working through the bankruptcy courts to secure support for settlements worth more than $10 billion and $1.6 billion, respectively. read more

The distributors have been in the midst of two trials nationally in the litigation, one in New York and one in West Virginia. They have now agreed to resolve the New York case, a person briefed on the matter said.

The deal with New York Attorney General Letitia James and the populous Long Island counties of Nassau and Suffolk comes three weeks into the first jury trial accusing companies of profiting from a flood of addictive painkillers that devastated communities. read more

Closing arguments are expected in the West Virginia trial next week. Local West Virginia communities had opted out of the proposed nationwide deal to pursue one on their own.

The New York trial will continue against three drugmakers accused of deceptively marketing their painkillers – Endo International Plc (ENDP.O), Teva Pharmaceutical Industries Ltd (TEVA.TA) and AbbVie Inc’s (ABBV.N) Allergan unit.

Reporting by Nate Raymond in Boston; Editing by Sandra Maler, Bill Berkot and Cynthia Osterman

Our Standards: The Thomson Reuters Trust Principles.

Read original article here

Hurricane Elsa cuts power, batters homes in Barbados

CHRIST CHURCH, Barbados, July 2 (Reuters) – Hurricane Elsa blew roofs off homes, toppled trees and sparked flooding in the island nation of Barbados then pounded St. Vincent with heavy rain and winds on Friday, as the storm was tracking towards Haiti.

Minister of Home Affairs, Information and Public Affairs Wilfred A. Abrahams urged Barbadians to shelter in place and only leave their homes if the structures were damaged.

Elsa strengthened into a hurricane earlier in the day and was about 95 miles (153 km) west-northwest of St. Vincent, blowing maximum sustained winds of 85 miles per hour (140 kph), the U.S. National Hurricane Center (NHC) said.

“The island definitely cannot handle any sort of damages at this point because we still haven’t recovered from the volcanic eruption yet,” said 20-year-old student Queriise Thomas in the community of Choppins in southern St. Vincent.

Earlier this year, heavy rains slammed St. Vincent with major flooding and landslides after a series of volcanic eruptions blanketed large swathes of the island in a thick layer of ash. read more

Thomas said intermittent heavy rain caused flooding and parts of the island lost electricity. St. Vincent’s water and sewage authority cut water supply to all residents as a precaution due to potential mudflows.

The NHC forecast 4 to 8 inches (10 to 20 cm) of rain with a maximum of 15 inches (38 cm) across the Windward and southern Leeward Islands including Barbados, which could lead to isolated flash flooding and mudslides.

A man views damage to a home after strong winds of Hurricane Elsa passed St. Michael, Barbados July 2, 2021. REUTERS/Nigel Browne

Read More

Hurricane conditions were expected in Haiti and possible in the Dominican Republic and Jamaica by late Saturday, the agency said.

The Barbados minister said damage was reported in the south of the island including power outages, fallen trees, flash flooding and damaged roofs.

Emergency services were unable to reach people, but there were no reports of injuries or deaths.

A resident in south Barbados, 43-year-old structural engineer Greg Parris, whose home lost power around 7 a.m., said: “It was scary. Most of us, we haven’t experienced anything like this for a while.”

Elsa’s progress should be monitored by the Windward Islands, Leeward Islands, the Virgin Islands, Puerto Rico, the Dominican Republic, Cuba and the Cayman Islands, the Miami-based NHC said.

Little change in Elsa’s strength was forecast over the next 48 hours and some decrease in winds is possible on Monday, the hurricane center said.

Elsa’s storm surge was expected to raise water levels by as much as 1 to 4 feet above normal tide levels in some areas. Puerto Rico could receive up to 5 inches of rain, the NHC.

Reporting by Robert Edison Sandiford in Christ Church, Barbados and Kate Chappell in Kingston, Jamaica; Additional reporting by Anthony Esposito in Mexico City and Nakul Iyer in Bengaluru; Editing by Janet Lawrence and Cynthia Osterman

Our Standards: The Thomson Reuters Trust Principles.

Read original article here